Crispr Therapeutics AG (CRSP)
Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?
CRSP's innovative pipeline shines, but the biotech does face regulatory risks and fierce competition.
Crispr Therapeutics: Betting On A One-Shot Future
Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascular franchise, especially CTX-310 and CTX-320, offers blockbuster potential with best-in-class efficacy and a compelling one-time treatment value proposition. Recent partnerships, like Sirius Therapeutics, expand Crispr's multi-modal platform and open new multi-billion dollar market opportunities in siRNA and beyond.
Biotech Stock for Options Bears to Target Right Now
Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end.
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon. Thank you, everyone, for joining us.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
